Cardiac events following radical radiotherapy for lung cancer
Dr Fei Sun - Leeds Cancer Centre, Leeds, UK
10 May 2019
ALK-positive NSCLC: Treatments and latest developments
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
29 Apr 2019
ALK-positive NSCLC: Current landscape
Dr Antonio Passaro and Prof Rafal Dziadziuszko
29 Apr 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
18 Apr 2019
Entrectinib in NTRK fusion-positive non-small cell lung cancer
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
18 Apr 2019
Using CT imaging to find radiomic signatures in surgically resected NSCLC
Giulia Mazzaschi - University Hospital Parma, Parma, Italy
18 Apr 2019
The role of afatinib in patients with EGFR NSCLC
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
18 Apr 2019
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination wit...
Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas
15 Apr 2019
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplifie...
Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA
15 Apr 2019
Using regionally delivered autologous mesothelin-targeted CAR T cells in the tre...
Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA
15 Apr 2019
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases
Dr Marina Garassino - National Tumor Institute, Milan, Italy
15 Apr 2019
MYSTIC: Developing biomarkers for metastatic NSCLC
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switze...
11 Apr 2019
